Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib versus placebo in advanced radioiodine-refractory papillary or poorly differentiated thyroid cancer
2013-000422-58Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in papillary thyroid cancer (PTC) and thyroid cancer comparing Caprelsa with Placebo (2 arms). Primary endpoint: Progression-free survival. Started May 2013; status: completed.
02
Drugs
vandetanib
03
Conditions
papillary thyroid cancer (PTC)thyroid cancer
Beyond the preview
Go deeper on 2013-000422-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000422-58.